In vitro activities of cellulase and ceftazidime, alone and in combination against Pseudomonas aeruginosa biofilms.

Publisher: BioMed Central Country of Publication: England NLM ID: 100966981 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2180 (Electronic) Linking ISSN: 14712180 NLM ISO Abbreviation: BMC Microbiol Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Anti-Bacterial Agents/*pharmacology ; Biofilms/*drug effects ; Ceftazidime/*pharmacology ; Cellulase/*pharmacology ; Pseudomonas aeruginosa/*drug effects; Bacterial Adhesion/drug effects ; Biofilms/growth & development ; Dose-Response Relationship, Drug ; Drug Synergism ; Humans ; Microbial Sensitivity Tests

Background: Biofilms are a main pathogenicity feature of Pseudomonas aeruginosa and has a significant role in antibiotic resistance and persistent infections in humans. We investigated the in vitro activities of antibiotic ceftazidime and enzyme cellulase, either alone or in combination against biofilms of P. aeruginosa.
Results: Both ceftazidime and cellulase significantly decreased biofilm formation in all strains in a dose-dependent manner. Combination of enzyme at concentrations of 1.25, 2.5, 5, and 10 U/mL tested with 1/16× MIC of antibiotic led to a significant reduction in biofilm biomass. Cellulase showed a significant detachment effect on biofilms at three concentrations of 10 U/mL, 5 U/mL, and 2.5 U/mL. The MIC, MBC, and MBEC values of ceftazidime were 2 to 4 µg/mL, 4 to 8 µg/mL, and 2048 to 8192 µg/mL. When combined with cellulase, the MBECs of antibiotic showed a significant decrease from 32- to 128-fold.
Conclusions: Combination of the ceftazidime and the cellulase had significant anti-biofilm effects, including inhibition of biofilm formation and biofilm eradication in P. aeruginosa. These data suggest that glycoside hydrolase therapy as a novel strategy has the potential to enhance the efficacy of antibiotics and helps to resolve biofilm-associated wound infections caused by this pathogen.
(© 2021. The Author(s).)

J Med Microbiol. 2012 May;61(Pt 5):662-671. (PMID: 22301617)
J Chin Med Assoc. 2018 Jan;81(1):7-11. (PMID: 29042186)
Sci Adv. 2016 May 20;2(5):e1501632. (PMID: 27386527)
Infez Med. 2018 Sep 1;26(3):226-236. (PMID: 30246765)
Biotechnol Lett. 2011 Sep;33(9):1897-904. (PMID: 21618024)
PLoS Genet. 2014 Jul 24;10(7):e1004518. (PMID: 25057820)
J Infect Chemother. 2018 Jun;24(6):428-433. (PMID: 29449129)
J Immunol. 2005 Dec 1;175(11):7512-8. (PMID: 16301659)
Burns Trauma. 2013 Jun 18;1(1):5-12. (PMID: 27574616)
Pol J Microbiol. 2013;62(3):327-30. (PMID: 24459841)
J Biotechnol. 2014 Dec 10;191:121-30. (PMID: 25240440)
Microbiol Mol Biol Rev. 2009 Jun;73(2):310-47. (PMID: 19487730)
Open Microbiol J. 2017 Apr 28;11:53-62. (PMID: 28553416)
J Antimicrob Chemother. 2014 Apr;69(4):1027-34. (PMID: 24408988)
Pathog Dis. 2013 Apr;67(3):159-73. (PMID: 23620179)
APMIS Suppl. 2013 May;(136):1-51. (PMID: 23635385)
Antimicrob Agents Chemother. 2017 Jan 24;61(2):. (PMID: 27872074)
Age Ageing. 2002 Mar;31(2):126-30. (PMID: 11937475)
Mar Drugs. 2019 May 24;17(5):. (PMID: 31137680)
Clin Microbiol Rev. 2006 Apr;19(2):403-34. (PMID: 16614255)
BMC Microbiol. 2019 Dec 12;19(1):291. (PMID: 31830915)
Int J Antimicrob Agents. 2009 Jun;33(6):525-31. (PMID: 19179053)
Antimicrob Agents Chemother. 2009 Mar;53(3):1204-9. (PMID: 19064900)
Peptides. 2014 Dec;62:32-7. (PMID: 25285879)
Biofouling. 2003 Apr;19(2):77-85. (PMID: 14618691)
Biochemistry (Mosc). 2011 Jun;76(6):622-35. (PMID: 21639842)
Antimicrob Agents Chemother. 2019 May 24;63(6):. (PMID: 30988141)
APMIS Suppl. 2014 Dec;(138):1-51. (PMID: 25399808)
Nat Rev Microbiol. 2010 Sep;8(9):623-33. (PMID: 20676145)
Cold Spring Harb Perspect Med. 2013 Apr 01;3(4):a010306. (PMID: 23545571)
Adv Appl Microbiol. 2014;86:1-40. (PMID: 24377853)
Chemotherapy. 2003 Jun;49(3):121-5. (PMID: 12815204)
J Wound Ostomy Continence Nurs. 2008 May-Jun;35(3):273-80. (PMID: 18496083)
PLoS One. 2020 Jun 25;15(6):e0235093. (PMID: 32584878)
PLoS One. 2016 Oct 13;11(10):e0164622. (PMID: 27736961)
Science. 1999 May 21;284(5418):1318-22. (PMID: 10334980)
Clin Microbiol Rev. 2002 Apr;15(2):167-93. (PMID: 11932229)
Sci Rep. 2018 Jul 16;8(1):10738. (PMID: 30013112)
Biofilm. 2020 Sep 01;2:100037. (PMID: 33447822)
BMC Res Notes. 2020 Jan 10;13(1):27. (PMID: 31924268)
Mycoses. 2012 Jan;55(1):80-5. (PMID: 21668524)
Infect Immun. 2008 Sep;76(9):4176-82. (PMID: 18591225)
Curr Microbiol. 2014 May;68(5):635-41. (PMID: 24445333)
Antimicrob Agents Chemother. 2013 Jan;57(1):196-204. (PMID: 23089750)

Keywords: Biofilm inhibition; Ceftazidime; Cellulase; MBEC; Pseudomonas aeruginosa

0 (Anti-Bacterial Agents)
9M416Z9QNR (Ceftazidime)
EC 3.2.1.4 (Cellulase)

Date Created: 20211217 Date Completed: 20220127 Latest Revision: 20231108

20240829

PMC8675527

10.1186/s12866-021-02411-y

34915848